Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 377,738
  • Shares Outstanding, K 230,328
  • Annual Sales, $ 9,500 K
  • Annual Income, $ -18,610 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta 1.74
  • Price/Sales 36.29
  • Price/Cash Flow N/A
  • Price/Book 18.34

Options Overview Details

View History
  • Implied Volatility 290.96% (+56.82%)
  • Historical Volatility 45.63%
  • IV Percentile 75%
  • IV Rank 25.77%
  • IV High 863.26% on 04/17/25
  • IV Low 92.31% on 08/18/25
  • Expected Move (DTE 9) 0.1955 (11.50%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 134
  • Volume Avg (30-Day) 307
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 12,085
  • Open Int (30-Day) 15,979
  • Expected Range 1.5045 to 1.8955

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.07
  • Number of Estimates 3
  • High Estimate -0.02
  • Low Estimate -0.14
  • Prior Year -0.01
  • Growth Rate Est. (year over year) -600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5750 +7.94%
on 12/30/25
1.8200 -6.59%
on 12/18/25
-0.0200 (-1.16%)
since 12/05/25
3-Month
1.5300 +11.11%
on 11/07/25
2.0900 -18.66%
on 11/03/25
-0.0100 (-0.58%)
since 10/06/25
52-Week
0.3651 +365.63%
on 04/09/25
2.0900 -18.66%
on 11/03/25
+1.1506 (+209.43%)
since 01/06/25

Most Recent Stories

More News
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions,...

LCTX : 1.7000 (+0.59%)
Lineage Cell Therapeutics Issues Letter to Stockholders

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions,...

LCTX : 1.7000 (+0.59%)
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen ® ) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 ...

LCTX : 1.7000 (+0.59%)
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions,...

LCTX : 1.7000 (+0.59%)
Anti-Aging Market Surges as $101M Competition Drives Demographic Revolution

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The global longevity biotech market exploded from $27.15 billion in 2024 toward $46.61 billion by 2033...

LXRX : 1.1400 (unch)
AVAI : 0.4300 (-5.95%)
LCTX : 1.7000 (+0.59%)
ARQT : 29.22 (-3.25%)
AMGN : 330.17 (+2.95%)
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

Initial Program Focus Will Be On Addressing Manufacturing Scale

LCTX : 1.7000 (+0.59%)
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

H.C. Wainwright 27 th Annual Global Investment Conference Presentation on September 8, 2025 ...

LCTX : 1.7000 (+0.59%)
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

Three-year term intended to advance preclinical development of ReSonance Up to $12 million of development...

LCTX : 1.7000 (+0.59%)
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen ® ) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 ...

LCTX : 1.7000 (+0.59%)
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced...

LCTX : 1.7000 (+0.59%)

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 1.7900
2nd Resistance Point 1.7600
1st Resistance Point 1.7300
Last Price 1.7000
1st Support Level 1.6700
2nd Support Level 1.6400
3rd Support Level 1.6100

See More

52-Week High 2.0900
Last Price 1.7000
Fibonacci 61.8% 1.4311
Fibonacci 50% 1.2275
Fibonacci 38.2% 1.0240
52-Week Low 0.3651

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar